Skip to content
This is an innovative assay in the field of Oncology.
This new test consists of a panel that includes 1021 genes and analyzes two important biomarkers, MSI and TMB, related to immunotherapy. In addition, it offers analysis of the Loss of Heterozygosity (LOH) phenomenon, which can be used as a biomarker for the selection of PARP inhibitors as part of therapy, allowing the physician to design an individualized treatment for the patient. This approach includes options such as immunotherapy, chemotherapy, PARP inhibitors, and participation in clinical trials.
In addition, prime DX Liquid analyzes genes associated with genetic predisposition to cancer, providing the physician with information about the patient’s potential for hereditary cancer syndrome.
2020 Genekor Medical S.A.. All Rights Reserved.
Web Design 
We use cookies that are absolutely necessary for the operation of this website and the provision of functions that you requested. These cookies remain enabled throughout your visit. Analysis cookies are installed in order to enhance your overall experience of browsing the site, to measure our audience, to collect useful information that will allow us to offer you information tailored to your interests. These cookies will be activated only if you give us your consent. By clicking "Accept " you give your consent to the use of analytics cookies; by clicking on "REJECT " or by continuing to browse the website without any choice, only the technically necessary cookies will be stored in your browser. Learn more about cookies at our Cookies Policy and click on Cookie settings to set and / or modify your cookie preferences. In case you would like to be informed about the use of cookies please contact the following email: dataprotection@genekor.com ACCEPT REJECT Privacy & Cookies Policy
